Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-9

Maybe a last post- for longer term holders a couple of positives through the journey like the CR at $1.50 now looks pretty good and the spike during c0-vid which gave a chance for locking in some money/profit. They do have some products in the market and some revenue.
CM joined Jan 2024 I think and I thought albeit late I would give her 6-9 months for some change. It’s well over 12 months now and despite some change, unless you want to start over again it’s pretty ordinary.
Did the chair take the easy option and was any wide search done for a replacement for JF? Too easy an option for him and he retains a friendly CEO. Looks the same management team survived also. Ah yes a board meeting that discussed more than jam or cream first on the scones??
Lot of positive speak around Petalion but nothing in detail. Dendrimers candidates been on offer for years now and no uptake? maybe the space has better options (cancer TTT’s).
Radiopharmaceuticals delayed till 2026. Slow growth for Viva gel and viraleze despite plenty of attention in the respective fields. They will likely survive and provide income for Board and Managers but I don’t see much as a shareholder. The strategy might mean less spend but not sure of future revenue also being compromised. Now the churn around 10c makes me think any upside will be capped. GLTA